Rating Change: Is EVOTEC (ETR:EVT) a Stock to Buy After Bankhaus Lampe KG Upgrade?

November 25, 2016 - By Linda Rogers

Rating Change:  Is EVOTEC (ETR:EVT) a Stock to Buy After Bankhaus Lampe KG Upgrade?

EVOTEC (ETR:EVT) Upgrade

In a analysts report shared with investors today, Bankhaus Lampe KG upped shares of EVOTEC (ETR:EVT) to a Buy rating. The firm currently has a EUR 6.50 target price on the stock. Bankhaus Lampe KG’s target price would suggest a potential upside of 8.15% from the stock’s current price.

Evotec AG (ETR:EVT) Ratings Coverage

Out of 5 analysts covering Evotec (ETR:EVT), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. €6.50 is the highest target while €4.10 is the lowest. The €6.30 average target is 5.18% above today’s (€5.99) stock price. Evotec has been the topic of 33 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Wednesday, August 12 by Oddo & Cie. As per Wednesday, October 5, the company rating was upgraded by Bankhaus Lampe. Bankhaus Lampe upgraded the shares of EVT in a report on Wednesday, April 6 to “Buy” rating. The firm has “Buy” rating given on Thursday, September 3 by Bankhaus Lampe. Bankhaus Lampe upgraded the shares of EVT in a report on Thursday, July 30 to “Buy” rating. The company was upgraded on Friday, March 11 by Bankhaus Lampe. Bankhaus Lampe upgraded it to “Buy” rating and €4.60 target price in Thursday, June 30 report. Oddo & Cie upgraded Evotec AG (ETR:EVT) rating on Saturday, October 1. Oddo & Cie has “Buy” rating and €5.60 price target. Bankhaus Lampe upgraded it to “Buy” rating and €4.50 target price in Friday, August 7 report. On Wednesday, November 11 the stock rating was upgraded by Bankhaus Lampe to “Buy”.

About 238,153 shares traded hands. Evotec AG (ETR:EVT) has risen 1.41% since April 22, 2016 and is uptrending. It has underperformed by 4.00% the S&P500.

Insitutional Activity: The institutional sentiment increased to 1.28 in Q2 2016. Its up 0.61, from 0.67 in 2016Q1. The ratio improved, as 14 funds sold all Evotec AG shares owned while 25 reduced positions. 9 funds bought stakes while 17 increased positions. They now own 9.16 million shares or 19.26% less from 11.35 million shares in 2016Q1.

Commonwealth Equity Services has invested 0.02% of its portfolio in Evotec AG (ETR:EVT). Moreover, Stratos Wealth Partners has 0.55% invested in Evotec AG (ETR:EVT) for 367,233 shares. The Florida-based Ladenburg Thalmann Services Inc has invested 0.03% in Evotec AG (ETR:EVT). Tortoise Invest Lc has invested 0% of its portfolio in Evotec AG (ETR:EVT). Janney Montgomery Scott Ltd Liability holds 0.01% or 20,420 shares in its portfolio. Tower Rech Capital Limited Com (Trc) has 300 shares for 0% of their US portfolio. Wells Fargo Communications Mn reported 597,252 shares or 0% of all its holdings. Mycio Wealth Prtn Ltd Liability Corp accumulated 10,305 shares or 0.04% of the stock. Hudock Grp Lc has 196 shares for 0% of their US portfolio. First Manhattan Communications has 1,000 shares for 0% of their US portfolio. Cambridge Invest reported 43,122 shares or 0.02% of all its holdings. Oppenheimer Communications Incorporated has 0.08% invested in the company for 130,426 shares. Lpl Financial Lc last reported 404,995 shares in the company. The Minnesota-based Punch & Inv Mngmt has invested 0.66% in Evotec AG (ETR:EVT). First Limited Partnership has 0.01% invested in the company for 90,434 shares.

Evotec AG is a drug discovery and development company. The company has a market cap of 796.32 million EUR. The Firm is engaged in providing drug discovery solutions to the pharmaceutical, biotechnology and academic sectors. It has a 44.12 P/E ratio. The Firm has two divisions: EVT Execute and EVT Innovate.

More news for Evotec AG (ETR:EVT) were recently published by: Businesswire.com, which released: “Evotec Enters Licence Agreement for Access to CRISPR-CAS9 Gene Editing Technology” on July 06, 2016. Businesswire.com‘s article titled: “Evotec AG Reports Results of First Nine Months of 2016” and published on November 10, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>